rilvegostomig + bevacizumab

Rilvegostomig + bevacizumab is a combination therapy under investigation for the first-line treatment of advanced hepatocellular carcinoma. **Rilvegostomig** is a bispecific monoclonal antibody targeting two immune checkpoint proteins: TIGIT and PD-1, both of which can be exploited by cancer cells to avoid immune detection. By blocking both TIGIT and PD-1, rilvegostomig enhances T cell activity and anti-tumor immune response. **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), suppressing new blood vessel formation (angiogenesis) and thus tumor growth. The combination aims to enhance both immune-mediated cancer cell killing and inhibit tumor vascular supply, providing a dual approach to therapy. This regimen is primarily being studied in a global Phase III clinical trial (ARTEMIDE-HCC) for advanced hepatocellular carcinoma in patients not eligible for curative or locoregional therapy[1][2][4][7].